Degarelix as an Intermittent Androgen Deprivation Therapy for One or More Treatment Cycles in Patients with Prostate Cancer

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 16K citations

Pharmacy, Oncology, Cancer Symptom Management +15

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction

Raymond C. Rosen, Alan Riley, Gorm Wagner et al. · Urology · 1997 · 5.8K citations

Medicine, Urology, Andrology +8

Guidelines on Prostate Cancer

Axel Heidenreich, Joaquim Bellmunt, M. Bolla et al. · 2013 · 864 citations

Medicine, Oncology, Urology +12

The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer

Laurence Klotz, L Boccon-Gibod, Neal D. Shore et al. · British Journal of Urology · 2008 · 614 citations · Full text

Medicine, Oncology, Pharmacology +17

Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

Maha Hussain, Catherine M. Tangen, Donna L. Berry et al. · New England Journal of Medicine · 2013 · 568 citations · Full text

Medicine, Oncology, Urology +14